TCGA-18-3421-01A-01R-0980-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.660
- MYC_TARGETS_V1+0.570
- MYC_TARGETS_V2+0.480
- MTORC1_SIGNALING+0.430
- E2F_TARGETS+0.420
- FATTY_ACID_METABOLISM+0.400
- ALLOGRAFT_REJECTION+0.310
- DNA_REPAIR+0.300
- ADIPOGENESIS+0.290
- GLYCOLYSIS+0.280
Top 10 suppressed
- MITOTIC_SPINDLE-0.460
- TGF_BETA_SIGNALING-0.380
- WNT_BETA_CATENIN_SIGNALING-0.350
- HEDGEHOG_SIGNALING-0.310
- APICAL_JUNCTION-0.280
- UV_RESPONSE_DN-0.280
- NOTCH_SIGNALING-0.240
- MYOGENESIS-0.180
- ESTROGEN_RESPONSE_EARLY-0.100
- PROTEIN_SECRETION-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-66-2778-01A-02R-0851-07 | — | cohortSQ1 | 0.864 |
| 2 | MDT-AP-0203 | Med | Medulloblastoma | 0.863 |
| 3 | TCGA-37-4133-01A-01R-1100-07 | — | cohortSQ1 | 0.862 |
| 4 | 94a92a4a-6c40-40c4-913d-0cdba8cb5892 | — | — | 0.849 |
| 5 | TCGA-18-3411-01A-01R-0980-07 | — | cohortSQ2 | 0.845 |
| 6 | TCGA-BH-A0HB-01A-11R-A056-07 | — | B | 0.836 |
| 7 | 77984740-019e-482f-822a-25a74ec2cc32 | — | — | 0.829 |
| 8 | TCGA-66-2771-01A-01R-0980-07 | — | cohortSQ1 | 0.827 |
| 9 | 8824c0fd-764e-4525-952b-f25efa742772 | — | — | 0.821 |
| 10 | TCGA-66-2795-01A-02R-0980-07 | — | cohortSQ2 | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.660 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.430 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.290 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.280 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.260 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |